Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity (2014 - 2026)

Collegium Pharmaceutical's Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 1.26% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $6.5 billion (up 8.78% YoY), while the FY2025 annual figure was $1.7 billion, changed 0.41% from the prior year.
• Liabilities and Shareholders Equity was $1.7 billion for Q1 2026 at Collegium Pharmaceutical, roughly flat from $1.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.7 billion in Q4 2024 to a low of $1.1 billion in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.2 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 92.88% in 2022, then declined 13.22% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.2 billion in 2022, then decreased by 2.63% to $1.1 billion in 2023, then surged by 45.51% to $1.7 billion in 2024, then retreated by 0.41% to $1.7 billion in 2025, then slipped by 0.29% to $1.7 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.7 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.